Therefore, in the future, we can try to evaluate the prognosis and risk stratification of patients by detecting the expression level of PRR11 in surgical specimens from BLCA patients, as well as develop immunotherapy drugs targeting PRR11 based on the immune microenvironment. The gene discussed is PRR11; the disease is bladder transitional cell carcinoma.